Table 4

Adverse events

Adverse event

Any grade

%

Grade 3

%


Yellow skin discoloration

25

59

-

-

Fatigue

24

57

1

2

Taste changes

22

52

-

-

Mucositits

21

50

0

0

Hypertension

19

45

7

17

Epigastralgia

15

36

0

0

Nausea/vomiting

14

33

0

0

Anorexia

12

29

2

7

Diarrhea

11

26

0

0

Facial edema

9

21

1

2

Hand and foot syndrome

6

14

0

0

Thyroid function abnormalities

5

12

0

0

Thrombopenia

5

12

1

2

Anemia

4

10

1

2

LVEF reduction*

3

7

1

2

Myalgia

3

7

0

0

Neutropenia

3

7

1

2

Constipation

2

7

0

0

Pneumothorax

1

2

1

2

Hemoptysis

2

7

0

0


There was one grade 5 adverse event (a patient who developed a massive pulmonary embolism, see text).

* Any grade: Reductions in LVEF more than 15% from baseline or LVEF less than 50%. Grade 3: 30–40%.

Kontovinis et al. BMC Cancer 2009 9:82   doi:10.1186/1471-2407-9-82

Open Data